Avelox Side Effects

Avelox is a fluoroquinolone antibiotic developed by Bayer AG. Complications associated with its use may include peripheral neuropathy, tendon injuries, aortic aneurysm, aortic dissection and more. Because some Avelox side effects are debilitating and have the potential to be permanent, the risks associated with the medication may outweigh its benefit for patients with certain uncomplicated infections.

Avelox Boxed Warnings

Avelox was approved by the U.S. Food & Drug Administration (FDA) in 1999. In 2008, the FDA ordered the manufacturers of Avelox and other fluoroquinolone antibiotics to add a boxed warning to the drugs’ labels regarding a potential for serious tendon injuries, including tendon ruptures. A second boxed warning added in 2011 noted that use of Avelox could worsen symptoms of myasthenia gravis including muscle weakness and life-threatening breathing problems.

In 2016, the boxed warning was updated to caution against the use of fluoroquinolones in patients with certain uncomplicated infections, including acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections. The label modification followed an FDA review which confirmed the drugs’ association with serious side effects involving the tendons, muscles, joints, nerves and central nervous system. According to the agency, such complications may occur together, and they may be permanent. Read More

Avelox and Peripheral Neuropathy

In 2013, the FDA asked the manufacturers of all oral fluoroquinolones to strengthen warnings regarding the drug’s potential to cause peripheral neuropathy and nerve damage. While these Avelox side effects had been mentioned on the label since 2004, the agency concluded that the prescribing information should better describe the potential for rapid onset and the possibility of permanence. Read More

Avelox and Aortic Injuries

In 2015, a study published in JAMA: Internal Medicine indicated that people taking Avelox or another fluoroquinolone were twice as likely to suffer an aortic aneurysm or dissection within 60 days of exposure. Fluoroquinolones have been associated with several collagen-related disorders, prompting the authors to speculate that the same mechanism might be behind these serious aortic complications.

Avelox Eye Injuries

In March 2016, French scientists reported findings that suggested current use of a fluoroquinolone drugs might increase the risk for retinal detachment by nearly 50%. Retinal detachment is a serious eye injury that occurs when the light-sensitive tissue at the back of the eye separates from its supporting structures. This complication has the ptoential to cause permanent vision loss. Read More

That same month, drug regulators in Canada added new retinal detachment warnings to the labels of Avelox and other fluoroquinolones. Read More

Fluoroquinolone Associated Disability (FQAD)

FQAD is the term for a “constellation of symptoms” reported among some patients treated with Avelox and other fluoroquinolone antibiotics. These side effects may include cardiovascular symptoms, musculoskeletal symptoms, symptoms of the nervous system, neuropsychiatric symptoms, sensory symptoms and skin abnormalities.

Legal Help for Victims of Avelox Side Effects

The nationwide law firm of Bernstein Liebhard LLP offers free legal reviews to the victims of Avelox side effects. If you experienced nerve damage, aortic aneurysm, aortic dissection, or any other complication that could be related to the use of this drug, please contact our office by calling (888) 994-5118.

  1. FDA (2008) “Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]” http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htm
  2. FDA (2013) “FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection” http://www.fda.gov/Drugs/DrugSafety/ucm365050.htm
  3. FDA (2016) “FDA announces safety labeling changes for fluoroquinolones” http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm500325.htm
  4. Health Canada (2016) “Summary Safety Review – Oral FLUOROQUINOLONES – Assessing the Potential Risk of Retinal Detachment” http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/fluoroquinolones-eng.php
  5. FDA (2016) “FDA Briefing Document” http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM467383.pdf
Last Modified: November 8, 2018

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us

RXInjuryHelp.com on Google+  RXInjuryHelp.com on Facebook  RXInjuryHelp.com on LinkedIn  RXInjuryHelp.com on Twitter  RXInjuryHelp.com on YouTube  RXInjuryHelp.com on Pinterest

Skip to content